WEBULL

How Investors May Respond To IDEAYA Biosciences (IDYA) Regaining Oncology Programs After GSK Collaboration Exit

Simply Wall St · 2d ago
  • Earlier in December 2025, GlaxoSmithKline notified IDEAYA Biosciences that it will terminate their 2020 collaboration and license agreement, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA within about 90 days.
  • This shift hands IDEAYA full control of two oncology assets while the company maintains its guidance that cash resources should last into 2030.
  • Next, we’ll examine how GSK’s exit from the collaboration reshapes IDEAYA’s investment narrative, particularly around pipeline control and partnership risk.

AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is IDEAYA Biosciences' Investment Narrative?

To own IDEAYA, you have to believe its precision oncology pipeline, led by darovasertib in metastatic and primary uveal melanoma, can ultimately justify a rich valuation and ongoing losses. The recent GSK exit hands IDEAYA full control of the Werner helicase (IDE275) and Pol Theta (IDE705) programs, but near term the key catalysts still sit elsewhere: the Phase 2/3 OptimUM-02 data in 2026, neoadjuvant darovasertib progress and new IND-stage assets like IDE034 and IDE574 moving into the clinic. With the company reiterating a cash runway into 2030, the GSK decision looks more like a shift in partnership risk than a hit to funding. The bigger question is whether an expensive, unprofitable company with a relatively new management team can convert its broad pipeline into durable value.

However, one emerging risk is IDEAYA shouldering more R&D and execution burden without GSK’s backing. According our valuation report, there's an indication that IDEAYA Biosciences' share price might be on the expensive side.

Exploring Other Perspectives

IDYA 1-Year Stock Price Chart
IDYA 1-Year Stock Price Chart
Community members on Simply Wall St peg IDEAYA’s fair value between US$49.65 and a very large US$617.80 across 2 views, underscoring how far opinions can stretch. Set that against the central near term catalyst in darovasertib and the growing reliance on self-funded R&D, and it becomes clear why you may want to weigh several perspectives before deciding how IDEAYA fits into your portfolio.

Explore 2 other fair value estimates on IDEAYA Biosciences - why the stock might be worth just $49.65!

Build Your Own IDEAYA Biosciences Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.